This site is intended for healthcare professionals

FDA Oncologic Drugs Advisory Committee voted in favor of maintaining accelerated approval of Tecentriq + Abraxane, for the treatment of unresectable locally advanced or metastatic triple-negative breast cancer. Genentech/Roche

Read time: 1 mins
Last updated:29th Apr 2021
Published:30th Apr 2021
Condition: Breast Cancer Triple Neg
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest